Post by icemandios on Aug 9, 2018 17:38:58 GMT
LabCorp Licensing MDNA Liquid Biopsy-Based Prostate Cancer Technology
Aug 08, 2018
| staff reporter
NEW YORK (GenomeWeb) – MDNA Life Sciences announced today an exclusive licensing agreement with Laboratory Corporation of America for a liquid biopsy-based noninvasive test for patients who may have prostate cancer.
Under the terms of the deal, which covers the US, LabCorp will be able to use MDNA's technology to develop and commercialize a test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
Financial and other terms of the agreement were not disclosed.
Based in West Palm Beach, Florida, MDNA is a molecular diagnostics company using liquid biopsy technology based on the mitochondrial genome. In late 2016 it launched its first noninvasive blood-based cancer test for prostate cancer test, signaling its move into the liquid biopsy space.
360-Dx
Leaflet
Aug 08, 2018
| staff reporter
NEW YORK (GenomeWeb) – MDNA Life Sciences announced today an exclusive licensing agreement with Laboratory Corporation of America for a liquid biopsy-based noninvasive test for patients who may have prostate cancer.
Under the terms of the deal, which covers the US, LabCorp will be able to use MDNA's technology to develop and commercialize a test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
Financial and other terms of the agreement were not disclosed.
Based in West Palm Beach, Florida, MDNA is a molecular diagnostics company using liquid biopsy technology based on the mitochondrial genome. In late 2016 it launched its first noninvasive blood-based cancer test for prostate cancer test, signaling its move into the liquid biopsy space.
"We believe that the future commercialization of this unique biomarker will have a significant impact on how prostate biopsy decisions are made going forward, and we are very excited to be working with LabCorp to increase patient access to this technology in the U.S. market," MDNA CEO Chris Mitton said in a statement.
360-Dx
MDNA Life Sciences Mitomic Prostate Test
Mar 19, 2018
MDNA Life Sciences has launched the Mitomic Prostate Test Real-Time PCR Kit for research use only in Europe. The liquid biopsy test is designed for the early detection of prostate cancer in advance of biopsy, is independent of PSA and age, and is available for licensee laboratories to conduct in-house validation studies and controlled testing. The assay targets the 3.4-kilobase mitochondrial DNA deletion and is designed for use on real-time PCR platforms. Each kit contains all necessary reagents to process up to 21 patient samples, MDNA said. The company noted that a CE-IVD version of the kit will be available in July.
Mar 19, 2018
MDNA Life Sciences has launched the Mitomic Prostate Test Real-Time PCR Kit for research use only in Europe. The liquid biopsy test is designed for the early detection of prostate cancer in advance of biopsy, is independent of PSA and age, and is available for licensee laboratories to conduct in-house validation studies and controlled testing. The assay targets the 3.4-kilobase mitochondrial DNA deletion and is designed for use on real-time PCR platforms. Each kit contains all necessary reagents to process up to 21 patient samples, MDNA said. The company noted that a CE-IVD version of the kit will be available in July.
Leaflet
Introducing a breakthrough liquid biopsy prostate cancer test
Who has prostate cancer and who doesn’t? Is it high-grade or low-grade?
The Mitomic™ Prostate Test from MDNA helps add a greater degree
of certainty to the testing pathway. It’s a simple, blood-based test
independent of PSA. With a 99% negative predictive value, it’s the most
accurate test available on the market.
of certainty to the testing pathway. It’s a simple, blood-based test
independent of PSA. With a 99% negative predictive value, it’s the most
accurate test available on the market.
It gives you and your patients the reassurance of a yes or no answer.
Helping to better inform the need for invasive biopsy surgery in men
with a PSA in the grey area between 1 and 10.
with a PSA in the grey area between 1 and 10.
The benefits are clear:
l Simple, blood-based test
l Independent of PSA, age and family history
l No algorithm
l Accurate yes/no result
l 99% negative predictive value
l 94% sensitivity
l Affordable
l Simple, blood-based test
l Independent of PSA, age and family history
l No algorithm
l Accurate yes/no result
l 99% negative predictive value
l 94% sensitivity
l Affordable
How Mitomic™ Technology works:
Mitomic™ Technology unlocks the power of mitochondrial DNA.
The mitochondrial genome is home to multiple copies of mitochondrial
DNA, some of which become mutated beyond repair when cells are
stressed by diseases such as cancer.
Mitomic™ Technology unlocks the power of mitochondrial DNA.
The mitochondrial genome is home to multiple copies of mitochondrial
DNA, some of which become mutated beyond repair when cells are
stressed by diseases such as cancer.
Our pioneering Mitomic™ tests can detect this mutated DNA, which
can accumulate from the very early stages of a disease, giving an
unparalleled opportunity to accurately detect the disease before it
even presents clinically.
can accumulate from the very early stages of a disease, giving an
unparalleled opportunity to accurately detect the disease before it
even presents clinically.
Mitomic™ Testing from MDNA